Jenya Antonova

PCR48 Common Criticism of Patient-Reported Outcomes (PRO) in Health Technology Assessments (HTA) by the Institute for Quality and Efficiency in Healthcare (IQWiG) in Breast Cancer and Non-Small Cell Lung Cancer (NSCLC)

Jenya Antonova, Niclas Kuerschner, Sarah Boehme, Magdalena Alicja Harrington

us, de (code pays fourni par la source)

Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial

Bhavana Pothuri, Sileny Han, Dana Meredith Chase, Florian Heitz et autres

OBJECTIVE: To assess patient-reported health-related quality of life (HRQoL) in patients with ovarian cancer (OC) who received niraparib as first-line maintenance therapy. METHODS: PRIMA/ENGOT-OV26/GOG-3012 (NCT02655016) enrolled patients with newly diagnosed advanced OC who responded to first-line platinum-based chemotherapy. Patients were randomized (2:1) …

us, be, de, es, il, fr, ca, it, dk, fi (code pays fourni par la source)

An Updated Review of Food and Drug Administration Warning and Untitled Letters for Clinical Outcome Assessment Claims Between 2013 and 2021

Lara Sams, Ashley F. Slagle, Tara L. Symonds, Jenya Antonova et autres

us, au (code pays fourni par la source)

The Incidence, Prevalence, and Associated Costs of Anemia, Malignancy, Venous Thromboembolism, Major Adverse Cardiovascular Events, and Infections in Rheumatoid Arthritis Patients by Treatment History in the United States

Robin K. Dore, Jenya Antonova, Chakkarin Burudpakdee, Lawrence Chang et autres

OBJECTIVE: Comorbidities in rheumatoid arthritis (RA) can influence treatment selection, impact treatment persistency, and increase health care costs. This study assessed the magnitude of comorbidity burden via epidemiology (incidence and prevalence) and associated costs of select comorbidities in RA patients: anemia, malignancy, …

us (code pays fourni par la source)

THU0555 HEALTHCARE COSTS IN PATIENTS WITH RHEUMATOID ARTHRITIS SWITCHING FROM THEIR FIRST CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG TO ANOTHER DISEASE-MODIFYING ANTIRHEUMATIC DRUG REGIMEN

Robin K. Dore, Jenya Antonova, Lawrence Chang, Magdaliz Gorritz et autres

us (code pays fourni par la source)

SAT0066 BURDEN OF MALIGNANCY, VENOUS THROMBOEMBOLISM, ANEMIA, AND INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO SWITCHED FROM A FIRST CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG TO ANOTHER DISEASE-MODIFYING ANTIRHEUMATIC DRUG REGIMEN

Robin K. Dore, Jenya Antonova, Lawrence Chang, Haibo Huang et autres

us (code pays fourni par la source)

AB1143 BURDEN OF GLUCOCORTICOIDS AMONG RHEUMATOID ARTHRITIS PATIENTS AT DIFFERENT STAGES OF DISEASE-MODIFYING ANTIRHEUMATIC DRUG MANAGEMENT

Robin K. Dore, Jenya Antonova, Magdaliz Gorritz, Lawrence Chang et autres

us (code pays fourni par la source)

TP3 THE CONSISTENCY OF US REAL-WORLD RHEUMATOID ARTHRITIS DISEASE-MODIFYING ANTIRHEUMATIC DRUG TREATMENT PATTERNS WITH AMERICAN COLLEGE OF RHEUMATOLOGY GUIDELINES

Robin K. Dore, Jenya Antonova, Lawrence Chang, Huan Huang et autres

us (code pays fourni par la source)

FRI0077 SHORT DURATION OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (CSDMARDS) BEFORE AND AFTER BECOMING A CSDMARD INADEQUATE RESPONDER IN RHEUMATOID ARTHRITIS PATIENTS

Robin K. Dore, Jenya Antonova, Huan Cheng Huang, Magdaliz Gorritz et autres

us (code pays fourni par la source)

SAT0142 DIFFERENCES IN PATIENT CHARACTERISTICS AND PATTERNS OF TREATMENT BY DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARD) IN BDMARD NAIVE VERSUS EXPERIENCED PATIENTS

Robin K. Dore, Leslie R. Harrold, Taylor S. Blachley, Kelechi Emeanuru et autres

us (code pays fourni par la source)

AB0363 TREATMENT PATTERNS IN RHEUMATOID ARTHRITIS PATIENTS INITIATING DMARDS: ANALYSIS OF US HEALTH PLAN CLAIMS

Robin K. Dore, Jenya Antonova, Jerrold W. Hill

us (code pays fourni par la source)

SAT0133 TREATMENT PATTERNS, PERSISTENCE, AND DURABILITY IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (BDMARDS)

Robin K. Dore, Jenya Antonova, Chakkarin Burudpakdee, Xin Wang et autres

us (code pays fourni par la source)